World Journal of *Gastrointestinal Surgery*

World J Gastrointest Surg 2020 December 27; 12(12): 468-563





Contents

Monthly Volume 12 Number 12 December 27, 2020

REVIEW

468 Carbohydrate antigen 19-9 – tumor marker: Past, present, and future Lee T, Teng TZJ, Shelat VG

ORIGINAL ARTICLE

Retrospective Study

491 Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncological outcomes

You L, Yao L, Mao YS, Zou CF, Jin C, Fu DL

507 Risk factors for postoperative stoma outlet obstruction in ulcerative colitis

Kitahara T, Sato Y, Oshiro T, Matsunaga R, Nagashima M, Okazumi S

Clinical Trials Study

520 Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study

Ince V, Carr BI, Bag HG, Ersan V, Usta S, Koc C, Gonultas F, Sarici BK, Karakas S, Kutluturk K, Baskiran A, Yilmaz S

SYSTEMATIC REVIEWS

534 Ectopic liver tissue (choristoma) on the gallbladder: A comprehensive literature review Akbulut S, Demyati K, Ciftci F, Koc C, Tuncer A, Sahin E, Karadag N, Yilmaz S

CASE REPORT

549 Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report

Zhang JW, Peng C, Ye YS, Li W

555 Individualized treatment for gastric cancer with rib metastasis: A case report

Zhang Y, Zhang ZX, Lu ZX, Liu F, Hu GY, Tao F, Ye MF

ABOUT COVER

Associate editor of World Journal of Gastrointestinal Surgery, Dr. Vishal G Shelat is a Senior Consultant Surgeon at Tan Tock Seng Hospital, Singapore. Having received his Bachelor's degree from Gujarat University (Ahmedabad, India) in 2000, Dr. Shelat undertook his postgraduate training first at B.J. Medical College and Civil Hospital (Ahmedabad, India), receiving his Master's degree in 2003, and then at the National University of Singapore, receiving his MD (General Surgery) in 2008. He became Consultant Surgeon in the Department of Surgery at Tan Tock Seng Hospital in 2014. His research interests include the application of evidence-based medicine in digestive diseases, particularly to study the effects of such integrative medicine methods on and management of diseasesyndrome pattern establishment. Currently, he serves as member of the Chapter of General Surgery, College of Surgeons of Singapore and Treasurer for the Singapore Hepatopancreaticobiliary Association. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2020 edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJGS as 1.863; IF without journal self cites: 1.824; Ranking: 109 among 210 journals in surgery; Quartile category: Q3; Ranking: 77 among 88 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL

World Journal of Gastrointestinal Surgery

ISSN 1948-9366 (online)

LAUNCH DATE

November 30, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Shu-You Peng, Varut Lohsiriwat, Jin Gu

EDITORIAL BOARD MEMBERS

https://www.wjgnet.com/1948-9366/editorialboard.htm

PUBLICATION DATE

December 27, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS

https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS

https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT

https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS

https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION

https://www.f6publishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



WJGS https://www.wjgnet.com

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Surg 2020 December 27; 12(12): 549-554

DOI: 10.4240/wjgs.v12.i12.549 ISSN 1948-9366 (online)

CASE REPORT

Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report

Jia-Wei Zhang, Cheng Peng, Yan-Shuo Ye, Wei Li

ORCID number: Jia-Wei Zhang 0000-0003-1107-4948; Cheng Peng 0000-0002-5338-5325; Yan-Shuo Ye 0000-0002-7884-9659; Wei Li 0000-0001-7917-7666.

Author contributions: Zhang JW initially identified the case, collected and organized the medical records, and performed an intensive revision of the manuscript; Peng C primarily drafted the article, accomplished the actual writing, selected the references, and drafted the discussion; Ye YS also performed the revision of the manuscript; Li W contributed to the conceptual design, and carried out critical revision and finalization of the manuscript.

Supported by Nature Science
Foundation of The Science and
Technology Bureau of Jilin
Province, No. Li 20190201227JC;
and The Innovation Capacity
Building Fund of The
Development and Reform
Commission of Jilin Province, No.
Li 2019C015.

Informed consent statement: The patient provided informed written consent for the publication of this case report.

Conflict-of-interest statement: None.

Jia-Wei Zhang, Cheng Peng, Yan-Shuo Ye, Wei Li, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China

Jia-Wei Zhang, Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Cheng Peng, Department of Hepatobiliary-Pancreatic Surgery, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China

Corresponding author: Wei Li, MD, PhD, Professor, Surgeon, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130033, Jilin Province, China. weili888@jlu.edu.cn

Abstract

BACKGROUND

Simple hepatic cysts are relatively common in adults, and mostly appear as asymptomatic incidental radiologic findings. Occasionally, a large cyst will cause symptoms. Elevations in the serum biomarkers protein induced by vitamin K absence (PIVKA)-II, cancer antigen (CA) 12-5, and CA19-9 are often associated with malignant tumors in the liver or bile ducts. This is the first report to describe a case of hepatic cyst with elevated levels of PIVKA-II and CA12-5.

CASE SUMMARY

An 84-year-old Chinese woman was admitted with gradual abdominal distension. Her symptoms started 1 year ago, and she had poor appetite and a weight loss of 5 kg within the past 2 wk. She denied any symptoms associated with abdominal pain, fever and chills, nausea and vomiting, etc. The abdomen was enlarged, more in the right upper quadrant, without tenderness. Laboratory examination showed significantly increased serum levels of PIVKA-II, CA12-5, and CA19-9. A computed tomography scan revealed multiple round cysts in the liver with clear boundaries. The largest cyst was 20.1 cm × 12.2 cm × 19.6 cm in size, located in the right lobe of the liver with mild dilatation of the intrahepatic bile duct, but there was no contrast enhancement. Percutaneous drainage on the largest hepatic cyst and polycinnamol sclerosing agent injection into the cyst cavity were performed. After treatment, the patient's symptoms relieved and the elevated serum tumor makers reduced to the normal levels dramatically.

CONCLUSION



CARE Checklist (2016) statement:

The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: htt p://creativecommons.org/License s/by-nc/4.0/

Manuscript source: Unsolicited

manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: China

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

Received: July 23, 2020 Peer-review started: July 23, 2020 First decision: October 6, 2020 Revised: October 16, 2020 Accepted: November 12, 2020 Article in press: November 12, 2020 Published online: December 27, 2020

P-Reviewer: Pfeiffer DC **S-Editor:** Gao CC L-Editor: Wang TQ P-Editor: Li JH



The present report identifies an unusual case of a giant hepatic cyst with marked elevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. After treatment, these three serum markers dramatically decreased to normal levels. The mechanisms for the elevation of these tumor markers may be as follows: (1) A giant hepatic cyst compresses the liver, causing injury to the hepatocytes, which may lead to secretion of a large amount of PIVKA-II; and (2) Some tumorassociated antigens, such as carcinoembryonic antigen, CA19-9, CA12-5, and CA15-3, are expressed on inflammatory cells.

Key Words: Hepatic cyst; Tumor markers; Protein induced by vitamin K absence-II; Cancer antigen 12-5; Cancer antigen 19-9; Case report

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Simple hepatic cysts typically appear as asymptomatic benign tumors of the liver without elevation of any diagnostic serum biomarkers. However, over the years, a few cases of simple hepatic cysts with elevated tumor markers have been reported in the world. Here, we report a case of giant simple hepatic cyst with elevation of multiple serum cancer biomarkers, including protein induced by vitamin K absence-II, cancer antigen (CA) 12-5, and CA19-9.

Citation: Zhang JW, Peng C, Ye YS, Li W. Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report. World J Gastrointest Surg 2020; 12(12): 549-554

URL: https://www.wjgnet.com/1948-9366/full/v12/i12/549.htm

DOI: https://dx.doi.org/10.4240/wjgs.v12.i12.549

INTRODUCTION

Simple hepatic cysts are generally regarded as congenital malformations. This is a relatively common finding in adults, with a reported incidence ranging from 3.5% to 10%^[1]. These cysts are usually small in size with abdominal symptoms occurring in less than 20% of the patients. Complications such as mass effect, rupture, hemorrhage, obstructive jaundice, and infection are rare, but may lead to the emergence of symptoms^[2]. Overall, simple hepatic cysts are benign and lack serum biomarkers for diagnosis. A giant simple hepatic cyst is uncommon^[3,4]. Serum protein induced by vitamin K absence (PIVKA)-II, cancer antigen (CA) 12-5, and cancer antigen CA19-9 are recognized as biomarkers for malignant tumor. These biomarkers are associated with hepatocellular carcinoma and bile duct carcinoma. Here, we report a rare case of giant simple hepatic cyst with marked elevation of serum PIVKA-II, CA12-5, and CA19-9 levels. We have found only one previous report of hepatic cyst with elevation of serum CA19-9^[5]. To the best of our knowledge, the present report is the first to describe a case of giant simple hepatic cyst with elevated serum cancer biomarker levels of PIVKA-II, CA12-5, and CA19-9.

CASE PRESENTATION

Chief complaints

An 84-year-old Chinese woman was admitted with gradual abdominal distension.

History of present illness

The patient's symptoms started 1 year ago. And she had poor appetite and a weight loss of 5 kg within the past 2 wk. She denied any symptoms associated with abdominal pain, fever and chills, nausea and vomiting, etc.

History of past illness

There was no prior history of trauma, hepatitis, allergy, or alcohol or tobacco usage.



WJGS https://www.wjgnet.com

Personal and family history

No special.

Physical examination

Physical examination showed that she was in medium nutritional status with an icteric appearance. Vital signs were within normal ranges. The abdomen was asymmetrically enlarged, more in the right upper quadrant, without tenderness. Bowel movements occurred about 3-4 times per minute.

Laboratory examinations

Laboratory examination showed significantly increased serum levels of PIVKA-II (> 30000 mAU/mL; reference: < 32 mAU/mL), CA12-5 (428 U/mL; reference: < 35 U/mL), and CA19-9 (51.67 U/mL; reference: < 39 U/mL). Serum aspartate aminotransferase (AST) (97.03 IU/L; reference: < 40 IU/L), alanine aminotransferase (ALT) (64.73 IU/L; reference: < 40 IU/L), total bilirubin (TBIL) (61.19 μmol/L; reference: < 21 μmol/L), and direct bilirubin (DBIL) (36.42 μmol/L; reference: < 3.4 μmol/L) levels were moderately increased. Serum prothrombin time (PT) (33.3 s; reference: 11.0-15.0 s) and activated partial thromboplastin time (aPTT) (54.0 s; reference: 28.0-43.5 s) levels were also elevated slightly. However, serum albumin (ALB) (23.88 g/L; reference: > 35 g/L), prealbumin (PLAB) (17.3 mg/L; reference: 180-390 mg/L), and choline esterase (CHE) levels (1750 IU/L; reference: 3000-13000 IU/L) were significantly low.

Imaging examinations

Following an initial abdominal ultrasound examination, an enhanced computed tomography (CT) scan was performed, which revealed multiple round cysts in the liver with clear boundaries. The largest cyst was located in the right lobe of the liver, with mild dilatation of the intrahepatic bile duct, and a size of approximately 20.1 cm × 12.2 cm × 19.6 cm. There was no contrast enhancement in either the arterial or venous phase (Figure 1).

FINAL DIAGNOSIS

Taking into account all of the patient's symptoms, signs, and radiology examinations, a clinical diagnosis of simple hepatic cyst was established.

TREATMENT

We performed percutaneous drainage on the largest hepatic cyst and injected polycinnamol sclerosing agent into the cyst cavity. Approximately 1150 mL of yellowish green liquid was drained the first day. The cystic fluid was examined, with the results showing some inflammatory cells, but no bacteria, neoplastic cells, or parasites.

OUTCOME AND FOLLOW-UP

After 1 wk of drainage, the patient's symptoms of abdominal distension and early satiety were gradually eased. Follow-up at 2 mo post cyst drainage found that the size of the cyst had been much reduced, from 20.1 cm \times 19.6 cm to 8.7 cm \times 6.1 cm (Figure 2), and the serum tests for liver function, coagulating function, PIVKA-II, and CA19-9 revealed that the levels were restored to normal ranges. The serum CA12-5 level remained slightly higher (84.5 U/mL; reference: < 35 U/mL) than normal, but it was significantly reduced from the previous level of 428 U/mL (Table 1).

DISCUSSION

Simple hepatic cysts are typically asymptomatic benign tumors of the liver. These cysts usually contain serous fluid, do not communicate with the biliary tree, and do not have separations. PIVKA II, also known as des-gamma-carboxy prothrombin

Table 1 Differences of the parameters post cyst drainage			
	Before drainage	After drainage	Reference
Size of the cyst	20.1 cm × 19.6 cm	8.7 cm × 6.1 cm	
PIVKA-II	> 30000 mAU/mL	Normal	< 32 mAU/mL
CA12-5	428 U/mL	84.5 U/mL	< 35 U/mL
CA19-9	51.67 U/mL	Normal	< 39 U/mL

(DCP), is an abnormal prothrombin molecule that is increased in malignant liver disease. During the malignant transformation of hepatocytes, the vitamin K-dependent carboxylase system becomes impaired, which leads to the production of PIVKA II[6,7]. CA12-5, which is derived from the coelomic epithelium including the endometrium, fallopian tubes, ovaries, and peritoneum, is commonly used for the diagnosis of epithelial cell ovarian cancer^[8]. CA19-9 is a glycoprotein macromolecule that can be elevated in digestive system tumors and in patients with benign hepatobiliary and gastrointestinal diseases[9,10].

Interestingly, in the present case, there were three tumor markers, including PIVKA-II, CA12-5, and CA19-9, that were elevated and then significantly decreased after decompression. The underlying mechanisms are unclear, and no previous reports have been published on this phenomenon. We propose that the elevation of ALT, AST, and TBIL levels in this patient might have resulted from the mass effect of liver compression by the giant hepatic cyst. This further led to liver function impairment, resulting in decreased levels of serum ALB and CHE as well as poor coagulation function. The giant hepatic cyst of the present patient compressed the intrahepatic bile ducts and caused obstructive jaundice. A similar case was reported by Mehtsun et al[11]. All of the present patient's laboratory indexes returned to normal ranges after intra-cystic drainage, further confirming that this series of liver function changes was indeed induced by the mass effect of the giant hepatic cyst.

Yanai et all[5] reported a case of simple hepatic cyst with elevated CA19-9, while cases of hepatic cysts with elevated PIVKA-II or CA12-5 have not previously been reported. We speculate that the mechanisms for the elevation of these tumor markers may be as follows: (1) A giant hepatic cyst compresses the liver, causing injury to the hepatocytes, which may lead to secretion of a large amount of PIVKA-II; (2) Some tumor-associated antigens, such as carcinoembryonic antigen (CEA), CA19-9, CA12-5, and CA15-3, are expressed on inflammatory cells[12,13]. We found inflammatory cells in the patient's cystic fluid, so we conjecture that elevated serum CA19-9 and CA12-5 levels are non-specific and might be due to the effect of inflammation; and (3) Although the exfoliative cytology examination of the patient's cystic fluid did not have a positive finding, CT scan showed no typical characteristics of serous tumor, and the tumor marker levels were significantly decreased after treatment. Therefore, the possible existence of serous tumors could not be completely ruled out because of lack of pathological examination of the cyst wall.

In summary, to the best of our knowledge, this is the first report of a giant simple hepatic cyst associated with the elevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. This case revealed that an abnormal elevation of tumor markers is possible in the benign condition of giant hepatic cyst. A significant decline in the levels of these markers can serve as a tool to evaluate the effectiveness of treatment.

CONCLUSION

The present report identifies an unusual case of giant hepatic cyst with marked elevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. After treatment, these three serum markers dramatically decreased to normal levels. The mechanisms for the elevation of these tumor markers may be as follows: (1) A giant hepatic cyst compresses the liver, causing injury to the hepatocytes, which may lead to secretion of a large amount of PIVKA-II; and (2) Some tumor-associated antigens, such as CEA, CA19-9, CA12-5, and CA15-3, are expressed on inflammatory cells.




Figure 1 Enhanced abdominal computed tomography before treatment. A: Arterial phase; B: Venous phase; C: Balanced phase.




Figure 2 Abdominal computed tomography at 2 mo after treatment.

REFERENCES

- Garcea G, Rajesh A, Dennison AR. Surgical management of cystic lesions in the liver. ANZ J Surg 2013; 83: 516-522 [PMID: 23316726 DOI: 10.1111/ans.12049]
- Blonski WC, Campbell MS, Faust T, Metz DC. Successful aspiration and ethanol sclerosis of a large, symptomatic, simple liver cyst: case presentation and review of the literature. World J Gastroenterol 2006; **12**: 2949-2954 [PMID: 16718826 DOI: 10.3748/wjg.v12.i18.2949]
- Asuquo M, Nwagbara V, Agbor C, Otobo F, Omotoso A. Giant simple hepatic cyst: a case report and review of relevant literature. Afr Health Sci 2015; 15: 293-298 [PMID: 25834563 DOI: 10.4314/ahs.v15i1.40]
- Day RJ, Sanchirico PJ, Pfeiffer DC. Giant hepatic cyst as a cause of gastric outlet obstruction. Radiol Case Rep 2019; 14: 1088-1092 [PMID: 31338132 DOI: 10.1016/j.radcr.2019.06.015]
- Yanai H, Tada N. A simple hepatic cyst with elevated serum and cyst fluid CA19-9 levels: a case report. J Med Case Rep 2008; 2: 329 [PMID: 18851758 DOI: 10.1186/1752-1947-2-329]
- Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52: 776-782 [PMID: 17253135 DOI: 10.1007/s10620-006-9541-2]
- Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int 2011; **31**: 22-35 [PMID: 20874725 DOI: 10.1111/j.1478-3231.2010.02348.x]
- Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS; International Collaboration to Harmonise Outcomes and Measures for Endometriosis. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG 2016; 123: 1761-1768 [PMID: 27173590 DOI: 10.1111/1471-0528.14055]
- Liu X, Cai H, Wang Y. Prognostic significance of tumour markers in Chinese patients with gastric cancer. ANZ J Surg 2014; 84: 448-453 [PMID: 23013163 DOI: 10.1111/j.1445-2197.2012.06287.x]
- Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, Yuan YH, Chen QK. Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer. Pathol Oncol Res 2015; 21: 83-95 [PMID: 24875250 DOI: 10.1007/s12253-014-9791-9]
- 11 Mehtsun WT, Patel MS, Markmann JF, Hertl M, Vagefi PA. Obstructive jaundice caused by a giant non-parasitic hepatic cyst. Ann Hepatol 2015; 14: 267-269 [PMID: 25671837 DOI: 10.1016/S1665-2681(19)30790-2]
- Szekanecz E, Sándor Z, Antal-Szalmás P, Soós L, Lakos G, Besenyei T, Szentpétery A, Simkovics E, Szántó J, Kiss E, Koch AE, Szekanecz Z. Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann N Y Acad Sci 2007; 1108: 359-371 [PMID: 17893999 DOI: 10.1196/annals.1422.037]
- Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ. Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care (Engl) 2017; 26 [PMID: 26853428 DOI: 10.1111/ecc.12446]



Published by Baishideng Publishing Group Inc

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: https://www.f6publishing.com/helpdesk

https://www.wjgnet.com

